Robert Luckett, MD
Gastroenterology · New Albany, INNPI 1972999050
Payments from drug & device makers
Across 372 payments — averaging $512.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$129K
- Phathom Pharmaceuticals, Inc.$56K
- AbbVie$1K
- Johnson & Johnson$618
- Takeda Pharmaceuticals U.S.A., Inc.$549
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$517
- plus $2K from 28 others
Across 1 payment — averaging $1898.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 5 | $129,182 |
| Phathom Pharmaceuticals, Inc. | 87 | $56,485 |
| AbbVie | 73 | $1,229 |
| Johnson & Johnson(2 entities) | 24 | $618 |
| Takeda Pharmaceuticals U.S.A., Inc. | 34 | $549 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 36 | $517 |
| Sanofi | 12 | $219 |
| Pfizer | 13 | $208 |
| Gilead | 9 | $172 |
| Ardelyx, Inc. | 9 | $168 |
| Merck | 9 | $156 |
| Regeneron Healthcare Solutions, Inc. | 6 | $138 |
| Bristol Myers Squibb | 7 | $120 |
| Endogastric Solutions, Inc | 2 | $111 |
| QOL Medical, LLC | 5 | $108 |
| Intercept Pharmaceuticals, Inc. | 6 | $104 |
| Daiichi Sankyo Inc. | 4 | $70 |
| Ironwood Pharmaceuticals, Inc | 3 | $55 |
| Alnylam Pharmaceuticals Inc. | 3 | $52 |
| Amgen | 3 | $48 |
| Janssen Scientific Affairs, LLC | 2 | $48 |
| Organon | 5 | $47 |
| Tersera Therapeutics LLC | 2 | $45 |
| Madrigal Pharmaceuticals | 2 | $42 |
| Fresenius Kabi USA, LLC | 2 | $30 |
| Aimmune Therapeutics, Inc. | 1 | $20 |
| Redhill Biopharma Inc. | 1 | $19 |
| Novo Nordisk | 1 | $19 |
| AMAG Pharmaceuticals, Inc. | 1 | $16 |
| Celltrion USA Inc. | 1 | $16 |
| Lilly USA, LLC | 1 | $15 |
| Ipsen Biopharmaceuticals, Inc | 1 | $15 |
| Sandoz | 1 | $13 |
| CSL Behring | 1 | $12 |
How this compares
$190,664 in reported general payments places this provider in the 90th percentile of 323 gastroenterology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other gastroenterology in New Albany
- Jonathan ObertNew Albany$758K
- David DresnerNew Albany$544K
- Matthew McColloughNew Albany$385K
- Steven HarrellNew Albany$125K
- Emori CarraraNew Albany$59K
- Abdul JabbarNew Albany$33K
- Monika FischerIndianapolis$2.8M
- Douglas RexIndianapolis$2.3M
- Pankaj PatelSouth Bend$2.3M
- David PoundIndianapolis$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.